US researchers develop new antibody that shows promise against malaria infection
A novel monoclonal antibody, developed by US researchers, has shown promise against malaria infection in an early clinical trial.
Researchers at the University of Maryland School of Medicine`s Center for Vaccine Development and Global Health (CVD) found that the antibody -- MAM01 -- provided dose-dependent full protection against the malaria parasite with minimal side effects.
"This new monoclonal antibody could transform how we prevent malaria in young children and pregnant women," said lead author Kirsten E. Lyke, Professor of Medicine at the varsity’s School of Medicine.
"Unlike vaccines that may require multiple doses or boosters, a single injection of a long-acting antibody could provide immediate, months-long protection. It`s a fundamentally different way to stop infection before...










